06 / Cultivated meat
Published reporting, research and funding records filed under Cultivated meat.
12 August 2026 · Cultivated meat · Manufacturing · Funding · Bioprocess
AgFunderNews reports that Believer Meats’ Israeli trustee has lengthened bidding for its cultivated-meat patents and know-how, while a separate court-led sale advances for the company’s North Carolina production facility.
12 August 2026 · Cultivated meat · Manufacturing · Bioprocess
A South Korean university study examined a soil-fungus polysaccharide as a cultivated-beef culture aid, reporting benefits during cell expansion and muscle formation while leaving important commercial questions unanswered.
12 August 2026 · Cultivated meat · Regulation · Manufacturing · Funding · Bioprocess
BeneMeat brought Czech meat-sector representatives inside its pilot facility to discuss cultivated-cell production, labeling and adoption, presenting incumbent processors as prospective customers rather than competitors.
7 August 2026 · Cultivated meat · Ingredients
SEED CONTENT — placeholder. Fat carries most of the flavour in meat, and it is the part cell agriculture has found hardest to make at useful volumes.
6 August 2026 · Regulation · Cultivated meat
SEED CONTENT — placeholder. The dossier leans on the same safety framework used in the first approval, with an added condition on labelling.
5 August 2026 · Cultivated meat · Regulation · Manufacturing
Aleph Farms has regulatory clearance for cultivated beef in Singapore and is preparing a restaurant debut, while partner facilities, production economics and undisclosed foodservice relationships shape its commercialization plan.
4 August 2026 · Cultivated meat · Regulation · Manufacturing
Food Standards Australia New Zealand is consulting on a cell-cultured duck ingredient application as consumer awareness remains limited and regulators prepare to assess feedback under newly established rules.
4 August 2026 · Cultivated meat · Manufacturing · Funding · Bioprocess
A patent roundup highlights how Hanwha Solutions, Tufts University and IamFluidics are addressing culture-medium expense and cell-recovery losses, while leaving commercial-scale performance and patent outcomes unsettled.